Description
Sanjeev Luther, President and CEO, Rafael Pharmaceuticals discusses how tumor cell metabolism has recently attracted substantial attention as an area for the development of drugs to treat cancer. Rafael is a company leading the field of cancer metabolism with their drug CPI-613 (devimistat) currently being tested in Phase 1, 2, and 3 clinical trials for patients with rare cancers, including pancreatic cancer, acute myeloid leukemia (AML) and Burkitt's lymphoma.
@RafaelPharma
#RafaelPharma #cancermetabolism #pancreaticcancer #CPI613
